Navigation Links
The development of a melanocortin MC5 receptor binding assay using the LEADseeker Multimodality Imaging System

Key words: Melanocortin • receptor binding assay • LEADseeker • SPA Imaging Beads

Pro-melanocortins are present in high levels in the pituitary and are processed into three major peptide hormone fragments: adrenocorticotrophin (ACTH), the melanocyte stimulating hormones, and β-endorphin. The various melanocyte stimulating hormones are known to activate the MC5 (melanocortin subtype 5) receptor. The melanocortin 5 receptor (MC5R) in particular is expressed in numerous human peripheral tissues including adrenal gland, leukocytes, and many others. The only firmly established function of MC5R is its participation in exocrine function particularly sebaceous gland secretion. The role of MC5R in exocrine secretion has the potential to be exploited for the treatment of skin disorders such as acne and dermatitis (1).

This application note describes a 384-well melanocortin MC5 receptor binding assay, which has been developed on the LEADseeker™ Multimodality Imaging System.

Products used

LEADseeker Multimodality Imaging System 18-1140-71

Wheat Germ Agglutinin (WGA) PEI RPNQ0289
Type B PS SPA Imaging Beads

[125I] (Nle4-D-phe7) α-Melanocyte IM316
Stimulating Hormone ([125I]α-MSH), direct labeled

Other materials required
Human recombinant melanocortin (Euroscreen, ES-194-M)
MC5 receptor membrane preparation*

NDP-α-MSH (Sigma, M-8764)

α-Melanocyte Stimulating (Sigma, M-4135)
Hormone (α-MSH)

β-Melanocyte Stimulating (Sigma, M-6513)
Hormone (β-MSH)

384-well white flat bottom polystyrene (Corning, 3705)
not treated microplates

Assay buffer: 25 mM HEPES, pH 7.4
5 mM MgCl2
1 mM CaCl2
1 mM 1,10 phenathroline monohydrate
0.2% (w/v) protease-free BSA

GraphPad Prism™ software (GraphPad Software)

* Use of the receptor in this application note is not permitted in North America and Australia. For further information on the use of this receptor in restricted territories, please contact Euroscreen’s Business Development and Licensing Manager at

Human recombinant melanocortin MC5 receptor membrane preparation produced in CHO-K1 cells was used in conjunction with [125I] NDP-α-MSH (2000 Ci/mmol) and WGA PEI Type B PS SPA Imaging Beads. Non-specific binding (NSB) was determined in the presence of 1-µM NDP-α-MSH. The standard assay format was as follows:

1. Reagents were added in the following order: assay buffer, unlabeled ligand (NSB wells), labeled ligand, and premixed bead and membrane*. Total assay volume was 40 µl.

2. Wells contained 10 µl (~ 44 000 dpm) of [125I] NDP-αMSH (0.25 nM/well), 0.125 mg of SPA Imaging Bead and 0.3125 µg of receptor preparation added tog ether in a 20-µl volume, and 10 µl of assay buffer in the absence of competing ligand. For competition assays, 10 µl of competing ligand prepared in assay buffer was added with [125I] NDP-α-MSH (10 µl, as above), premixed bead and receptor (20 µl), also giving a total assay volume of 40 µl.

3. NSB wells contained 10 µl of [125I] NDP-α-MSH (0.25-nM/well), 0.125 mg of SPA Imaging Bead and 0.3125 µg of receptor preparation added together in a 20-µl volume, and 10 µl of 4-µM unlabeled NDP-α-MSH (final concentration 1 µM).

4. For DMSO tolerance studies, DMSO was diluted in assay buffer to give final concentrations per well as shown in the results.

5. Plates were sealed and incubated overnight at room temperature (20–25 ºC).

6. Following incubation, plates were imaged on the LEADseeker Multimodality Imaging System for 5 min with quasi-coincident averaging and 3 ×3 binning.

7. For background estimation, bead-only wells (0.125 mg of bead/well, 10 µl), plus assay buffer (30 µl) were included in all experiments. Typically, backgrounds exhibited from bead-only wells were less than 10 integrated optical density (IOD) units and were routinely subtracted from total and NSB values during data analyses.

* Bead and diluted membrane were premixed at room temperature prior to assay addition.

Kd determination
Saturation binding was carried out with dilutions of [125I] NDP-α-MSH to give a range of concentrations from 1.53 pM to 8.62 nM in the assay wells. Figure 1 shows the saturation curve which was fitted using non-linear regression with the data analysis package GraphPad Prism v4.0. A Kd value of 0.518 nM (95% conf idence intervals 0.4557 to 0.5803 nM) was estimated directly from the curve.

DMSO tolerance
Dilutions of DMSO were prepared in assay buffer to give a range of concentrations from 1 to 10% DMSO (v/v) in the assay wells. The results in Figure 2 show that the assay is DMSO tolerant to 2% (v/v). Above 2% DMSO, an elevation in NSB is observed.

IC50 determination
Competition binding of 0.25-nM (~ 44 000 dpm) [125I] NDP-α-MSH with unlabeled NDP-α-MSH, and α-MSH were assessed and the IC50 values calculated as shown in Figure 3. For the competition assays, the unlabeled ligands NDP-α-MSH and α-MSH were prepared in assay buffer. The IC50 value for NDP-α-MSH was 0.1881 nM (95% confidence interval range 0.1525 to 0.2319 nM), Ki for NDP-α-MSH 0.1262 nM (95% confidence interval range 0.1024 to 0.1556 nM). The IC50 value for α-MSH was 26.66 nM (95% confidence interval range 20.76 to 34.24 nM), Ki for α-MSH was 17.89 nM (95% confidence interval range 13.93 to 22.98 nM).

Time course
A time course experiment was carried out using reagent concentrations as described in the protocol. Measurements were made over an assay incubation time of 20 h. The assay reached equilibrium after 5-h incubation at room temperature and the signal was stable for at least another 5 h (Fig 4).

Z’ analysis
A Z’ analysis was carried out using 48 replicate values for total and NSB wells. Z’ was 0.83 (Fig 5), which confirmed the robustness of the assay (2).

The melanocortin MC5 receptor binding a ssay has been successfully miniaturized to a 384-well format on LEADseeker Multimodality Imaging System and is suitable for high-throughput screening. The assay is tolerant up to 2% DMSO (v/v); is robust, exhibiting a Z’ value of 0.83, and has a stable signal of at least 10 h.

1. The Melanocortin System. Am. J. Physiol. Endocrinol. Metab. 284, E468–E474 (2003).

2. Zhang, J. et al, J. Biomol. Screening 4, 67–73 (1999).

back to top


Page: All 1 2 3 4 5

Related biology technology :

1. The development of a CXCR2 chemokine receptorbinding assay using the LEADseeker Multimodality Imaging System
2. The development of a melanocortin MC4 receptor binding assay using the LEADseeker Multimodality Imaging System
3. The development of a calcitonin-gene related peptide (CGRP) receptor-binding assay using the LEADseeker Multimodality Imaging System
4. The development of a somatostatin sst4 receptor-binding assay using the LEADseeker Multimodality Imaging System
5. The development of a serotonin 5-HT2C receptor-binding assay using the LEADseeker Multimodality Imaging System
6. Screening for potential beta 2-adrenergic receptor antagonists using CypHer5E and IN Cell Analyzer 1000
7. The use of CypHer5 for receptor internalization studies in both a range of GPCRs and a non-GPCR
8. The use of CypHer5E and the IN Cell Analyzer 1000 for live-cell receptor internalization studies
9. Screening for β2-adrenergic receptor agonists using the pH-sensitive dye,CypHer5, and the IN Cell Analyzer 3000
10. Development of a histamine H1 receptor binding assay using the LEADseeker Multimodality Imaging System
11. Development of a sensitive enzyme fragment complementation assay for cyclic adenosine 3, 5 monophosphate and its validation for pharmacological screening at G protein-coupled receptors
Post Your Comments:

(Date:6/23/2016)... -- Houston Methodist Willowbrook Hospital has signed a ... serve as their official health care provider. As ... provide sponsorship support, athletic training services, and most ... athletes and families. "We are excited ... to bring Houston Methodist quality services and programs ...
(Date:6/23/2016)... FRANCISCO , June 23, 2016   EpiBiome ... has secured $1 million in debt financing from Silicon ... ramp up automation and to advance its drug development ... its new facility. "SVB has been an ... beyond the services a traditional bank would provide," said ...
(Date:6/23/2016)... 2016 Apellis Pharmaceuticals, Inc. today announced ... of its complement C3 inhibitor, APL-2. The trials ... dose studies designed to assess the safety, tolerability, ... in healthy adult volunteers. Forty subjects ... single dose (ranging from 45 to 1,440mg) or ...
(Date:6/23/2016)... ... 23, 2016 , ... ClinCapture, the only free validated electronic ... showcase its product’s latest features from June 26 to June 30, 2016 for ... Disrupting Clinical Trials in The Cloud during the conference. DIA (Drug Information ...
Breaking Biology Technology:
(Date:6/7/2016)... , June 7, 2016  Syngrafii Inc. and ... business relationship that includes integrating Syngrafii,s patented LongPen™ ... project. This collaboration will result in greater convenience ... credit union, while maintaining existing document workflow and ... ...
(Date:6/2/2016)... The Department of Transport Management (DOTM) ... million US Dollar project, for the , Supply ... Enrolment, and IT Infrastructure , to ... implementation of Identity Management Solutions. Numerous renowned international vendors participated ... was selected for the most compliant and innovative ...
(Date:6/2/2016)... 2016 Perimeter Surveillance & Detection ... Physical Infrastructure, Support & Other Service  The ... offers comprehensive analysis of the global Border Security ... revenues of $17.98 billion in 2016. Now: ... leader in software and hardware technologies for advanced video ...
Breaking Biology News(10 mins):